经皮激光消融治疗甲状腺结节:1492例患者中位随访10年以上的疗效与安全性
该研究评估了超声引导下经皮激光消融治疗良性甲状腺结节的长期疗效与安全性,纳入2009年5月至2024年7月接受单次治疗的1492例患者。中位随访10.4年(非毒性结节)和11.4年(毒性结节)显示,结节体积持续缩小,无严重并发症,轻微并发症包括发热(15%)、疼痛(7%)和血肿(1%)。
要点
- 非毒性结节1年体积缩小中位数为70.7%,10年降至64.1%;毒性结节分别为63.8%和56.9%。
- 随访前3年无良性结节再生长(≥25%)病例。
- 无严重并发症,轻微并发症为发热(15%)、疼痛(7%)、血肿(1%)。
核心结论
- 超声引导下激光消融对非毒性和毒性良性甲状腺结节具有长期疗效和安全性,中位随访10年以上。
研究设计与样本
- 回顾性队列研究,纳入2009年5月至2024年7月接受单次激光消融治疗的1492例患者(非毒性结节1291例,毒性结节201例共211个结节)。
主要发现
- 非毒性结节中位随访10.4年(范围1-18年),毒性结节中位随访11.4年(范围3-15年)。
- 非毒性结节体积缩小中位数1年为70.7%,10年为64.1%;毒性结节分别为63.8%和56.9%(所有时间点与治疗前比较P < .001)。
- 随访前3年无良性结节再生长≥25%的病例。
- 停用甲巯咪唑的患者比例随结节体积增大而降低,从结节<5 mL的100%降至结节>25 mL的33.3%。
- 无严重并发症;轻微并发症包括发热(15%)、疼痛(7%)和血肿(1%)。
临床怎么用
- 对于良性非毒性和毒性甲状腺结节,超声引导下激光消融可作为长期有效的治疗选择。
- 结节体积较小的毒性结节患者停用甲巯咪唑的可能性更高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Previous studies have shown the efficacy and safety of percutaneous laser ablation for the treatment of nontoxic and toxic benign thyroid nodules; however, data on long-term follow-up are limited. OBJECTIVE: This work aimed to evaluate the long-term efficacy and safety of percutaneous, ultrasound-guided laser ablation of benign thyroid nodules. METHODS: Between May 2009 and July 2024, 1492 patients underwent a single treatment with laser ablation (nontoxic nodules, N = 1291; toxic nodules, N = 201 [211 nodules]). Nodule volume was assessed before treatment, then every 6 months in the first 3 years and annually thereafter. RESULTS: Median durations of follow-up were 10.4 years (range, 1-18 years) for nontoxic nodules and 11.4 years (range, 3-15 years) for toxic nodules. For nontoxic nodules, median volume reduction (VRR) was 70.7% at 1 year, reducing to 64.1% at 10 years. For toxic nodules, the corresponding VRR values were 63.8% and 56.9%, respectively (P < .001 vs pretreatment at all time points). No cases of benign nodule regrowth of 25% or greater occurred during the first 3 years of follow-up. The percentage of patients discontinuing methimazole treatment decreased with increasing nodule volume, from 100% for nodules smaller than 5 mL to 33.3% for nodules larger than 25 mL. No major complications were reported; overall, minor complications consisted of fever (15% of patients), pain (7%), and hematoma (1%). CONCLUSION: In the largest cohorts reported to date, ultrasound-guided laser ablation of thyroid lesions showed long-term efficacy and safety for treatment of nontoxic and toxic nodules, based on median follow-ups of 10 years or more.
引用
- Gambelunghe G, Del Sindaco P, Morettini F, et al. Percutaneous Laser Ablation for Thyroid Nodules: Efficacy and Safety in 1492 Patients With Median Follow-up of 10 Years or More. J Clin Endocrinol Metab. 2026. PMID: 41132004. doi:10.1210/clinem/dgaf581
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。